A Phase 2 interventional study of Experimental: YB-101 and Placebo YB-101 in Graves' Disease, sponsored by Yarrow Bioscience, Inc.. Recruiting at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Yarrow Bioscience, Inc. · Phase 2, Interventional, and Treatment
Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.
Among the 43 studies in Graves Disease with a site in United States, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 10 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 9 of the 17 other live ones, and was the 40th registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:
Sling Therapeutics, Inc. · Sites in United States
Biogen · Sites in United States, Puerto Rico
Appalachian State University · Sites in United States
Ethyreal Bio, Inc. · Sites in United States
Biohaven Therapeutics Ltd. · Sites in United States, Canada, Puerto Rico
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 10 · Phase 4 4
First in 1993; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 232 is above the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 76 across the 33 interventional studies, 42 across the 10 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yarrow Bioscience, Inc. as lead sponsor.
Yarrow Bioscience, Inc. has 1 study filed under Graves Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05435547Indiana UniversityPreoperative Corticosteroids in Autoimmune Thyroid Disease | 2026-12-30 |
| NCT07413874Appalachian State UniversityTelehealth Music Therapy for Adults With Endocrine Disorder and Depression | 2026-12-31 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
| NCT06980649Biohaven Therapeutics Ltd.Study of BHV-1300 in Graves' Disease | 2027-09 |
Among the 43 studies in Graves Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.
The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.
Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In Part 1, participants will receive YB-101 via subcutaneous injection. Part 2 participants will receive YB-101 via subcutaneous injection.
Drug: Experimental: YB-101
In Part 1, participants will receive placebo via subcutaneous injection. Part 2 participants will receive placebo via subcutaneous injection.
Drug: Placebo YB-101
YB-101 is administered over a 24 week period.
Placebo will be administered over a 24 week period.
Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Time frame: Baseline, Day 169
Proportion of participants with normal free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) who discontinued anti-thyroid drugs (ATDs), regardless of concomitant levothyroxine use
Time frame: Baseline, Day 169
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.